Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene’s Breakup with Celgene/BMS Now Complete with Return of BeiGene Shares

publication date: Aug 8, 2023

Beijing’s BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene, worth about $340 million. In 2017, the two companies announced a $1.4 billion cooperation agreement that sent ex-Asia rights for BeiGene’s PD-1 to Celgene, while BeiGene acquired marketing rights to three Celgene products in China. In 2020, Chinese authorities banned BeiGene-Celgene’s Abraxane because of manufacturing errors. BeiGene hasn’t sold the drug since then. Soon after the 2017 deal, Celgene was acquired by BMS, which already had a blockbuster PD-1, Opdivio. BMS returned the PD-1 rights to BeiGene along with a $150 million termination payment. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160; SHA: 688235)

Share this with colleagues: